50 results about "Barrier integrity" patented technology

This invention concerns a method for stimulating barrier integrity in a subject by administering to a subject a composition comprising docosapentaenoic acid (22:5 n3; DPA). Also the invention concerns a composition comprising DPA and eicosapentaenoic acid (EPA).

The present invention provides for the development of endocytosis-sensitive probes, and a remote method for measuring cellular endocytosis. These probes are based on the reduced water permeability of a nanoparticle or liposomal delivery system, and inherent degradability or disruption of barrier integrity upon endocytosis. The invention also provides for liposomes having combined therapeutic and diagnostic utilities by co-encapsulating ionically coupled diagnostic and therapeutic agents, in one embodiment, by a method using anionic chelators to prepare electrochemical gradients for loading of amphipathic therapeutic bases into liposomes already encapsulating an imaging agent. The invention provides for imaging of therapeutic liposomes by inserting a lipopolymer anchored, remotely sensing reporter molecules into liposomal lipid layer. The invention allows for an integrated delivery system capable of imaging molecular fingerprints in diseased tissues, treatment, and treatment monitoring.

An on-chip redundant crack termination barrier structure, or crackstop, provides a barrier for preventing defects, cracks, delaminations, and moisture / oxidation contaminants from reaching active circuit regions. Conductive materials in the barrier structure design permits wiring the barriers out to contact pads and device pins for coupling a monitor device to the chip for monitoring barrier integrity.

The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: cicosapentacnoic acid (EPA), docosahexacnoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

A new formulation for making a polyvinyl chloride (PVC, usually referred as vinyl in glove industry) glove has been disclosed in this invention. The resulting glove shows the following superior barrier integrity characteristics by comparing with current vinyl gloves in the market:Much lower in use failure rateImproved puncture strength and tensile strengthBetter chemical resistanceThe invention provides formulations to make compounds and methods to make such gloves. The new formulations and procedures could be easily realized economically under common vinyl glove production lines. Depending on the desired applications, both powdered and powder free gloves could be produced in the same formula.

The present invention relates generally to a peripheral marker or markers of blood barrier integrity and methods of using same in the diagnosis, prognosis, and treatment of a variety of diseases. The peripheral marker(s) of the present invention are particularly useful in the differential diagnosis of diseased states. The preferred embodiments of the present invention relate to methods, compositions, kits, and assays useful in determining the integrity or permeability of either a blood CSF barrier or a blood brain barrier. The various embodiments of the present invention can be used to identify subjects at risk for developing a disease associated with increased permeability of the blood brain barrier, as well as to provide insight on the ability of an agent or agents to pass through the blood brain barrier. Embodiments of the present invention preferably involve the use of subject derived blood samples to determine the occurrence and level of circulating proteins indicative of blood brain barrier permeability or integrity. The embodiments of the present invention also provides screening methods for diagnosis, prognosis, susceptibility, or degree of permeability of penetration of the blood brain barrier by detecting the presence of serum Transthyretin either directly or through the use of antibodies.

The present invention provides lactobacillus reuteri for preventing ulcerative colitis. The strain is named as lactobacillus reuteri RAM0101 and deposited on May 27, 2019 at China General Microbiological Culture Collection Center and has a preservation number of CGMCC NO.17853. C57BL / 6N mice are used as test objects, dextran sodium sulfate (DSS) is used to induce the mice to form an ulcerative colitis model and the model is also used to investigate effectiveness of the strain in preventing the ulcerative colitis. The lactobacillus reuteri can relieve weight loss, diarrhea, hematochezia and disease activity index (DAI) score of the ulcerative colitis mice induced by the DSS, protects pathological damages of colon tissues of the mice induced by the DSS, can enhance colon tissue epithelial barrier completeness and is also free of toxin and harms.

A receptacle for enclosing low-voltage electronic devices and maintaining the integrity of a vapor barrier. The receptacle forms a cavity having an open side. The receptacle may be mounted within a wall having a vapor barrier and an outer layer. The vapor barrier may be sealed to the receptacle and the outer layer and the vapor barrier may extend over the receptacle to enclose the space within the cavity, thereby forming an airtight enclosure.

An improved method is provided for etching back a tungsten layer that overlies a titanium nitride adhesion layer on a semiconductor structure. This method includes the steps of: (1) performing a first plasma etchback of the tungsten layer for a first predetermined time period, such that a thin layer of tungsten remains over the adhesion layer at the end of the first plasma etchback, (2) actively or passively cooling the resulting semiconductor structure to a temperature of 35° C. or lower, and then (3) performing a second plasma etchback of the tungsten layer until an endpoint is detected, thereby exposing the adhesion layer. Cooling the semiconductor structure prior to the second plasma etchback ensures that the titanium nitride adhesion layer is at a relatively low temperature during the second plasma etchback. The titanium nitride adhesion layer etches significantly slower at lower temperatures, thereby making it easier to stop the second plasma etchback on the adhesion layer.

An assay and a method for identifying a prebiotic to treat a subject in need thereof to promote intestinal barrier integrity or to blunt an inflammatory response are provided.

The invention relates to a method for evaluating the integrity of a well cementing barrier. The method includes the following steps that 1, a simulated formation of a tubular structure with the open upper end and the closed lower end is manufactured; 2, the manufactured simulated formation is put in a barrel; 3, a casing pipe coated with a drilling fluid layer is put in the simulated formation; 4, an ultrasonic probe is arranged in the middle in the casing pipe, and the ultrasonic probe is electrically connected with an oscilloscope, a pulse generation receiving instrument and a high-speed transient signal acquisition instrument, wherein the oscilloscope, the pulse generation receiving instrument and the high-speed transient signal acquisition instrument are arranged outside; 5, water is injected into the barrel till the water surface reaches an upper end opening of the simulated formation, and the casing pipe is filled with water; 6, cement paste is prepared; 7, the cement paste is injected between the casing pipe and the inner wall of the simulated formation, after injection is completed, water is injected into the barrel till the water surface is flush with the upper end face of the casing pipe, and waiting on cement setting is carried out; 8, the ultrasonic probe is started, the pulse generation receiving instrument is used for measuring and acquiring a well cementing acoustic amplitude curve of a to-be-measured time point, and the peak value of the first wave of the well cementing acoustic amplitude curve is read out; 9, whether the cell cementing integrity is qualified or not is judged according to the well cementing barrier integrity criterion.

The invention discloses lactobacillus plantarum capable of improving facial sensitive skin and repairing skin barriers, and belongs to the technical field of microorganisms and the technical field of medicines. The invention provides a strain of lactobacillus plantarum CCFM1158, and the lactobacillus plantarum CCFM1158 can relieve human cell barrier injury, which is specifically embodied in that (1) the survival rate of SDS-induced HaCaT cells is obviously improved; (2) the barrier damage caused by the SDS-induced HaCaT cells is obviously improved; (3) the cell migration capability is obviously promoted; and (4) the strain can effectively promote the expression of a natural moisturizing factor and a barrier integrity factor FLG, so that the lactobacillus plantarum CCFM1158 has a huge application prospect in preparation of products for preventing or treating skin barrier injury.

The invention discloses a rapid screening method and application of bifidobacterium capable of relieving colitis and belongs to the technical field of biology. The bifidobacterium pseudocatenulatum is preserved in China Center for Type Culture Collection (CCTCC), Wuhan, on July 5, 2021, and the preservation number is CCTCC M2021820. The bifidobacterium pseudocatenulatum can be used for significantly improving weight loss, colon length and disease activity index of mice during DSS-inducing colitis, enhancing intestinal barrier integrity, and inhibiting tissue damage, myeloperoxidase (MPO) activity, PGE2 level and proinflammatory factors. Compared with mice of a model group, the bifidobacterium pseudocatenulatum KLDS N2 has the advantages that the expression of proinflammatory cytokine mRNA of a DSS stimulated mouse is obviously down-regulated, and the expression of mRNA of mucoprotein and tight junction protein is up-regulated.

The invention provides a method for evaluating lung injury caused by nanoparticles based on organ-on-a-chip technology. A chip is mainly prepared by bonding and sealing an upper PDMS layer and a lowerPDMS layer and comprises a matrix inlet pool, two cell inlet pools, a waste liquid pool, a cell culture chamber and a matrix chamber. The chip is vertically inoculated with vascular endothelial cellsand alveolar epithelial cells separately, and culture is carried out for a certain period of time so as to form a lung air-blood barrier. Nanometers are added into an alveolar epithelial cell culturechamber, and monocytes are added into a vascular endothelial cell culture chamber in the manner of perfusion to simulate monocytes in the circulating blood of people, so an in-vitro nanoparticle lunginjury evaluation model is established. The nanoparticle lung injury evaluation model based on the chip can simulate the injury of the nanoparticles to the lung air-blood barrier, monitors destroy tothe integrity of the barrier in real time, realizes observation of the responses of two types of cells of the air-blood barrier, and traces the motion of the monocytes in real time.

The invention provides a strain of clostridiumbutyricum for preventing ulcerative colitis. The strain is preserved in CGMCC (China General Microbiological Culture Collection Center) on May 27, 2019, and the preservation number is CGMCC NO.17854. A C57BL / 6N mouse is used as an experiment object; DSS (Dextran Sulfate Sodium) is used for inducing the mouse to form an ulcerative colitis model; and themodel is used for investigating the effectiveness of the strain of the invention for preventing the ulcerative colitis. The clostridiumbutyricum provided by the invention can be used for effectivelyrelieving the body weight loss, diarrhea and hematochezia of the mouse with the ulcerative colitis induced by the DSS and effectively improving the DAI (Disease Activity Index) grade; the mouse colontissue pathologic lesion of the mouse induced by DSS can be protected; the epithelial barrier completeness of the colon tissues can be enhanced; and non-toxicity and harmlessness are realized.

A method of forming a barrier layer on the surface of an opening defined in a porous, low dielectric constant (low k), layer, has been developed. The method features the use of a two step deposition procedure using a physical vapor deposition (PVD), procedure to initially deposit a thin underlying, first component of the barrier layer, while an atomic layer deposition (ALD), procedure is then employed for deposition of an overlying second barrier layer component. The underlying, thin barrier layer component obtained via PVD procedures is comprised with the desired properties needed to interface the porous, low k layer, while the overlying barrier layer component obtained via ALD procedures exhibits excellent thickness uniformity.

A receptacle for enclosing low-voltage electronic devices and maintaining the integrity of a vapor barrier. The receptacle includes a base, and four side walls. Each side wall is joined to two adjacent side walls to form a perimeter wall. The perimeter wall is joined to the base and extends from it in a generally perpendicular fashion. The perimeter wall and base delineate a generally rectangular enclosure with five closed sides and one open side. A mounting flange is joined to the four side walls and extends from them in a generally perpendicular fashion. The receptacle is positioned within a wall of a building so as to allow at least one flange direct contact with a structural member. The structural members of the wall and the receptacle are both covered with a barrier film. The barrier film is sealingly attached to the flange. A hole is created through the barrier film within the confines of the receptacle so that a low voltage electronic device can be mounted in the wall without compromising the vapor barrier of the building.

The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.

The present invention provides compositions (for example, nutritional compositions or therapeutic compositions) that comprise a probiotic component, colostrum, a protein component, and a detoxification component. The compositions may further comprise a prebiotic component, a tissue constituent component, a symptomatic relief component, a cellular bioenergetics component, a tissue healing component, and / or an enzyme component. Also provided are methods of preventing or treating a disturbance in the integrity of a tissue barrier and / or a mucosal membrane adjacent to or on a tissue of an individual and preventing or treating resulting diseases or conditions by administering such compositions to the individual.

The invention provides a novel coronavirus intestinal infection model construction method based on a micro-fluidic organ chip, and particularly aims at simulating and constructing a series of intestinal tissue pathophysiological changes such as intestinal barrier integrity damage, mucus secretion abnormity and intestinal immune response activation occurring after novel coronavirus infection. The micro-fluidic chip is mainly composed of two layers of micro-channels, the channels are separated by a polydimethylsiloxane wedge-shaped porous membrane, each layer of channel is provided with an inlet and an outlet, and a static or dynamic environment can be formed through fluid. By respectively inoculating intestinal epithelial cells and endothelial cells into the upper channel and the lower channel on the chip and introducing circulating immune cells into the lower channel after virus infection, the miniature intestinal tissue on the chip is formed. Novel coronavirus particles are added into an upper channel of the chip, so that novel coronavirus exposure of intestinal tissues is simulated. The invention provides a multi-factor participated tissue level research system for the research of the SARS-CoV-2 infected intestinal pathogenesis.

The invention concerns a method for stimulating barrier integrity in a mammal by administering to a mammal a composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

The invention relates to an improvement of completeness of an intestinal barrier, in particular to a method for exciting the barrier completeness of mammalian by applying a composition containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA) and at least two different oligosaccharides to the mammalians.

The invention discloses a wireless communication device. The wireless communication device comprises at least one ultrasonic channel, and each ultrasonic channel comprises a first transducer arrangedon one side of a metal barrier, a first signal processing circuit connected with the first transducer, a second transducer arranged on the other side of the metal barrier and a second signal processing circuit connected with the second transducer. According to the wireless communication device, ultrasonic waves which are not in the auditory range of human ears are adopted as information conversionmedia to penetrate through the metal barrier to be used for information transmission, and high-speed and error-free information transmission is achieved under the condition that the integrity of themetal barrier is not damaged. According to the wireless communication device, the electromagnetic acoustic transducer is adopted, non-contact ultrasonic transmitting and receiving with a metal barrierare achieved, the installation procedures of the wireless communication device are reduced, meanwhile, rapid disassembling is achieved, and the cost is reduced.